Ticker brief
ROIV
last close
·
1 day
·
14 days
·
mkt cap
·
signals 14d
15
authors 14d
11
crowd 14d
+1.6σ
No price history on file for this name (likely non-equity or unlisted) — the “since then” column below stays blank.
Sentiment — last 14 days
daily mean sentiment, 2026-08-17 → 2026-08-27 · now +0.51 (−1 bearish … +1 bullish)
Who spoke11
| author | grade | trader score | signals | mean sent |
|---|---|---|---|---|
| @OzmosiHealth | C | · | 5 | +0.43 |
| @StockMKTNewz | C | +0.59 | 1 | +0.45 |
| @KeithTradeSmith | C | +0.25 | 1 | +0.30 |
| @Profericcoleman | C | -1.31 | 1 | +0.45 |
| @BiopharmIQ | B | · | 1 | +0.00 |
| @OracleNYSE | C | -0.08 | 1 | +0.50 |
| @AlertsAndNews | C | -1.90 | 1 | +0.50 |
| @CrweWorld | C | · | 1 | +0.50 |
| @BPharmCatalyst | C | · | 1 | +0.55 |
| @adamfeuerstein | A | +1.41 | 1 | +0.50 |
| @fwpharma | B | +0.98 | 1 | +0.50 |
Recent signals15of 15 in 14d — receipts included
| date (PT) | author | sent | what they said | since then | receipt |
|---|---|---|---|---|---|
| 2026-08-27 | @fwpharma | +0.50 | Priovant's inhibitor received FDA approval for dermatomyositis. | · | tweet ↗ |
| 2026-08-27 | @OzmosiHealth | +0.50 | FDA approved LISRAYA for adults with dermatomyositis. | · | tweet ↗ |
| 2026-08-27 | @OzmosiHealth | +0.50 | FDA approved LISRAYA for adults with dermatomyositis. | · | tweet ↗ |
| 2026-08-27 | @OzmosiHealth | +0.50 | Priovant announced FDA approval of LISRAYA for adult dermatomyositis. | · | tweet ↗ |
| 2026-08-27 | @OzmosiHealth | +0.50 | Priovant announced FDA approval of LISRAYA for adult dermatomyositis. | · | tweet ↗ |
| 2026-08-27 | @adamfeuerstein | +0.50 | FDA approved Roivant's Lisraya therapy for a rare autoimmune disease. | · | tweet ↗ |
| 2026-08-27 | @BPharmCatalyst | +0.55 | FDA approved Priovant's LISRAYA as the first targeted dermatomyositis therapy. | · | tweet ↗ |
| 2026-08-27 | @CrweWorld | +0.50 | Reports FDA approval of the first oral drug indicated for adult dermatomyositis. | · | tweet ↗ |
| 2026-08-27 | @AlertsAndNews | +0.50 | Reports FDA approval and US availability of LISRAYA for dermatomyositis. | · | tweet ↗ |
| 2026-08-27 | @OracleNYSE | +0.50 | FDA approved the first oral drug for adult dermatomyositis. | · | tweet ↗ |
| 2026-08-26 | @OzmosiHealth | +0.15 | Reports publication of Phase 3 skin-specific trial outcomes in JAMA Dermatology. | · | tweet ↗ |
| 2026-08-26 | @BiopharmIQ | +0.00 | Lists biotech opening moves and associated catalysts across multiple names. | · | tweet ↗ |
| 2026-08-17 | @Profericcoleman | +0.45 | Lists stocks reaching fresh 52-week highs as evidence of strong market breadth. | · | tweet ↗ |
| 2026-08-17 | @KeithTradeSmith | +0.30 | Reports new all-time or yearly highs across banks, energy and healthcare. | · | tweet ↗ |
| 2026-08-17 | @StockMKTNewz | +0.45 | Lists stocks reaching new 52-week highs today | · | tweet ↗ |
“Since then” = price move from the close on the signal's date (PT) to the latest close — what happened after they said it, not a backtest. A — means no trading session has closed since the signal yet. Sentiment is our extracted per-tweet score, −1…+1.